Dabogratinib
Dabogratinib, formerly known by its development code TYRA-300, is an investigational, orally administered small-molecule tyrosine kinase inhibitor that selectively targets fibroblast growth factor receptor 3 (FGFR3).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Dabogratinib, formerly known by its development code TYRA-300, is an investigational, orally administered small-molecule tyrosine kinase inhibitor that selectively targets fibroblast growth factor receptor 3 (FGFR3). It is being developed by Tyra Biosciences for FGFR3-associated cancers and achondroplasia.
As of October 2026, its clinical development included studies in urothelial carcinoma, non-muscle-invasive bladder cancer, and children with achondroplasia. AdisInsight listed phase II development for achondroplasia, bladder cancer, and urogenital cancer, and phase I/II development for solid tumors.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1379052920 under CC BY-SA 4.0; modifications have been made.